Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | IDE | P14735 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 10/20 | 0.47 |
| ▸ | CA1 | P00915 | 10/20 | 0.47 |
| ▸ | CA2 | P00918 | 10/20 | 0.47 |
| ▸ | CA9 | Q16790 | 10/20 | 0.47 |
| ▸ | HLCS | P50747 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biotin SCHEMBL20495575 | 0.89 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL6734256 | 0.89 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL30081014 | 0.83 | TDP1 (0.53) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL30058455 | 0.82 | TDP1 (0.64) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL24220337 | 0.81 | TDP1 (0.55) | TDP1PKMCA12CA1CA2 | |
| Biotin SCHEMBL10612975 | 0.80 | TDP1 (0.65) | TDP1MEN1ABL1LMNAPKM | |
| Histidine SCHEMBL2269187 | 0.79 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL31364275 | 0.78 | TDP1 (0.72) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL29462121 | 0.78 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL29460474 | 0.77 | TDP1 (0.67) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103797-A1 | ANTI-B7H4 SINGLE-DOMAIN ANTIBODY AND USE THEREOF | 博生吉医药科技(苏州)有限公司 | 2026-05-21 | — | — | WO | disclosed |
| EP-4744731-A2 | ANTI-HUMAN P40 PROTEIN DOMAIN ANTIBODY AND USE THEREOF | Akeso Biopharma, Inc. (CN) | 2026-05-20 | — | — | EP | disclosed |
| CN-122036946-A | Anti-B7H 4 single domain antibody and application thereof | 博生吉医药科技(苏州)有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4739716-A1 | EGFR/C-MET BISPECIFIC BINDING PROTEIN AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739715-A1 | EGFR/C-MET BISPECIFIC BINDING PROTEIN AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20260116972-A1 | CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXCD3, IGF-1RXCD3 OR FAPALPHAXCD3 BISPECIFIC SINGLE CHAIN ANTIBODY | AMGEN RES MUNICH GMBH (DE) | 2026-04-30 | — | — | US | disclosed |
| EP-4725500-A2 | ANTI-CEACAM5 ANTIBODIES AND CONJUGATES AND USES THEREOF | Merck Patent GmbH (DE) | 2026-04-15 | — | — | EP | disclosed |
| US-12595300-B2 | Anti-human P40 protein domain antibody and use thereof | AKESO BIOPHARMA, INC. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-20260092115-A1 | FC VARIANTS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2026-04-02 | — | — | US | disclosed |
| EP-4208481-B1 | ANTI-CEACAM5 ANTIBODIES AND CONJUGATES AND USES THEREOF | MERCK PATENT GMBH (DE) | 2026-03-04 | — | — | EP | disclosed |
| CN-114366746-A | Treatment of cancer using oxoisoindole compounds | 细胞基因公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-114344307-A | Treatment of cancer using oxoisoindole compounds | 细胞基因公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-114286827-A | Humanized anti-IL 17A antibodies and uses thereof | 神州细胞工程有限公司 | 2022-04-05 | — | — | CN | disclosed |
| WO-2022058618-A2 | SARS-COV2 ANTIBODIES | IONTAS LIMITED (GB) | 2022-03-24 | — | — | WO | disclosed |
| WO-2022048883-A1 | ANTI-CEACAM5 ANTIBODIES AND CONJUGATES AND USES THEREOF | MERCK PATENT GMBH (DE) | 2022-03-10 | — | — | WO | disclosed |
| CN-114057877-A | anti-PD-L1 antibody and application thereof | 百奥泰生物制药股份有限公司 | 2022-02-18 | — | — | CN | disclosed |
| EP-3954709-A1 | BISPECIFIC ANTIBODIES SPECIFIC FOR PD1 AND TIM3 | F. Hoffmann-La Roche AG (CH) | 2022-02-16 | — | — | EP | disclosed |
| WO-2022028608-A1 | ANTI PD-L1 ANTIBODY AND APPLICATION THEREOF | 百奥泰生物制药股份有限公司 | 2022-02-10 | — | — | WO | disclosed |
| US-20220041736-A1 | CROSS-SPECIES-SPECIFIC SINGLE DOMAIN BISPECIFIC SINGLE CHAIN ANTIBODY | AMGEN RESEARCH (MUNICH) GMBH (DE) | 2022-02-10 | — | — | US | disclosed |
| CN-107206072-B | Combination therapy of the T cell activating bispecific antigen binding molecule CD3 ABD folate receptor 1(FolR1) and a PD-1 axis binding antagonist | 豪夫迈·罗氏有限公司 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595300-B2 | Anti-human P40 protein domain antibody and use thereof | FCGRT, FCGR3B, VSIG8 | TDP1 1471/4885MEN1 2957/4885ABL1 3243/4885 |
| US-20260092115-A1 | FC VARIANTS | FCGR3B, FCGR2A, FCGR1A | TDP1 184/4885MEN1 3186/4885ABL1 287/4885 |
| US-20260116972-A1 | CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXCD3, IGF-1RXCD3 OR FAPALPHAXCD3 BISPECIFIC SINGLE CHAIN ANTIBODY | MET, IGF1R, INHA | TDP1 3260/4885MEN1 217/4885ABL1 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.